High-level resistance to isoniazid and ethionamide in multidrug-resistant Mycobacterium tuberculosis of the Lisboa family is associated with inhA double mutations

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 8, 2013, Pages 1728-1732

  Machado, Diana ^a   Perdigão, João ^b   Ramos, Jorge ^a   Couto, Isabel ^a,c   Portugal, Isabel ^b   Ritter, Claudia ^d   Boettger, Erik C ^d   Viveiros, Miguel ^a  

^a INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^b RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^c UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^d UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

LAM family; MDR TB; Resistance levels; Tuberculosis

Indexed keywords

ETHIONAMIDE; ISONIAZID;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL MUTATION; CONCENTRATION RESPONSE; DRUG SENSITIVITY; GENOTYPE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POINT MUTATION; PROMOTER REGION; STRUCTURAL GENE; VARIABLE NUMBER OF TANDEM REPEAT;

LAM FAMILY; MDR-TB; RESISTANCE LEVELS; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ETHIONAMIDE; GENOTYPE; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MOLECULAR TYPING; MUTATION; MYCOBACTERIUM TUBERCULOSIS; OXIDOREDUCTASES; PORTUGAL; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84880761362     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt090     Document Type: Article

References (20)

1. Hazbón M, Brimacombe M, del Valle M et al. Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2006; 50: 2640-9.
2. Vilchèze C, Wang F, Arai M et al. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat Med 2006; 12: 1027-9.
3. Morlock G, Metchock B, Sikes D et al. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2003; 47: 3799-805.
4. Viveiros M, Martins M, Couto I et al. Molecular tools for rapid identification and novel effective therapy against MDRTB/XDRTB infections. Expert Rev Anti Infect Ther 2010; 8: 465-80.
5. Perdigão J, Macedo R, João I et al. Multidrug-resistant tuberculosis in Lisbon, Portugal: a molecular epidemiological perspective. Microb Drug Resist 2008; 14: 133-43.
6. Springer B, Lucke K, Calligaris-Maibach R et al. Quantitative drug susceptibility testing of Mycobacterium tuberculosis using MGIT960 and the EpiCenter instrumentation. J Clin Microbiol 2009; 47: 1773-80.
7. Machado D, Couto I, Perdigão J et al. Contribution of efflux to the emergence of isoniazid and multidrug resistance in Mycobacterium tuberculosis. PLoS ONE 2012; 7: e34538.
8. Supply P, Allix C, Lesjean S et al. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol 2006; 44: 4498-510.
9. Allix-Béguec C, Harmsen D, Weniger T et al. Evaluation and strategy for use of MIRU-VNTRplus, a multifunctional database for online analysis of genotyping data and phylogenetic identification of Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2008; 46: 2692-9.
10. Demay C, Liens B, Burguiere T et al. SITVITWEB-a publicly available international multimarker database for studying Mycobacterium tuberculosis genetic diversity and molecular epidemiology. Infect Genet Evol 2012; 12: 755-66.
11. Brossier F, Veziris N, Truffot-Pernot C et al. Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011; 55: 355-60.
12. Leung E, Ho P, Yuen K et al. Molecular characterization of isoniazid resistance in Mycobacterium tuberculosis: identification of a novel mutation in inhA. Antimicrob Agents Chemother 2006; 50: 1075-8.
13. Hazbón M, Motiwala AS, Cavatore M et al. Convergent evolutionary analysis identifies significant mutations in drug resistance targets of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2008; 52: 3369-76.
14. David S, Duarte EL, Leite CF et al. Implication of the RDRio Mycobacterium tuberculosis sublineage in multidrug resistant tuberculosis in Portugal. Infect Genet Evol 2012; 12: 1362-7.
15. Fenner L, Egger M, Bodmer T et al. Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2012; 56: 3047-53.
16. Falzon D, Jaramillo E, Schünemann H et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-28.
17. Direcção-Geral da Saúde. Programa Nacional de Luta Contra a Tuberculose. Ponto da Situação Epidemiológica e de Desempenho de 2011. Relatório para o Dia Mundial da Tuberculose, avaliação preliminar em Março 2012. Direcção-Geral da Saúde, Lisboa, Portugal, 2012.
18. Direccão-Geral da Saúde. Programa Nacional de Luta Contra a Tuberculose. Ponto da Situagao Epidemiológica e de Desempenho de 2010. Relatório para o Día Mundial da Tuberculose, avaliacao preliminar em Marco 2011. Direccão-Geral da Saúde, Lisboa, Portugal, 2011.
19. Direccão-Geral da Saúde. Programa Nacional de Luta Contra a Tuberculose. Ponto da Situagao Epidemiológica e de Desempenho de 2009. Relatório para o Día Mundial da Tuberculose, avaliagao preliminar em Margo 2010. Direccão-Geral da Saúde, Lisboa, Portugal, 2010.
20. Portugal I, Covas MJ, Brum L et al. Outbreak of multiple drug-resistant tuberculosis in Lisbon: detection by restriction fragment length polymorphism analysis. Int J Tuberc Lung Dis 1999; 3: 207-13.